Literature DB >> 35551362

CMV infection combined with acute GVHD associated with poor CD8+ T-cell immune reconstitution and poor prognosis post-HLA-matched allo-HSCT.

Ze-Ying Fan1, Ting-Ting Han1, Wei Zuo1, Xiao-Su Zhao1, Ying-Jun Chang1, Meng Lv1, Xiao-Dong Mo1, Yu-Qian Sun1, Yuan-Yuan Zhang1, Yu Wang1, Lan-Ping Xu1, Xiao-Hui Zhang1, Kai-Yan Liu1, Xiao-Jun Huang1, Xiang-Yu Zhao1,2.   

Abstract

Cytomegalovirus (CMV) infection and acute graft-versus-host disease (aGVHD) are two major complications that contribute to a poor prognosis after hematopoietic stem cell transplantation (HSCT). Superior early immune reconstitution (IR) is associated with improved survival after HSCT. However, when all three factors, CMV infection, aGVHD, and IR, are concomitantly considered, the effects of the triple events on HSCT are still unknown and should be studied further. Thus we enrolled 185 patients who were diagnosed as hematological malignancies and treated with HLA-matched sibling transplantation (MST) between January 2010 and December 2014, of whom 83 were positive for CMV infection and 82 had aGVHD. Results showed that patients with both aGVHD and CMV infection had significantly higher non-relapse mortality (NRM), lower overall survival (OS), and delayed CD8+ T-cell IR. Multivariate analyses showed that both aGVHD combined with CMV infection and delayed CD8+ T-cell IR were independent risk factors for prognosis post-MST. Recurrent CMV infections are associated with poor CD8+ T-cell reconstitution. However, superior IR could protect against the negative effects of aGVHD and CMV infection on the transplant outcomes.
© The Author(s) 2022. Published by Oxford University Press on behalf of the British Society for Immunology. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.

Entities:  

Keywords:  CMV infeciton; IR; aGVHD; allo-HSCT

Mesh:

Year:  2022        PMID: 35551362      PMCID: PMC9226149          DOI: 10.1093/cei/uxac047

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   5.732


  29 in total

1.  Cytomegalovirus-specific T cells are primed early after cord blood transplant but fail to control virus in vivo.

Authors:  Suzanne M McGoldrick; Marie E Bleakley; Abraham Guerrero; Cameron J Turtle; Tori N Yamamoto; Shalini E Pereira; Colleen S Delaney; Stanley R Riddell
Journal:  Blood       Date:  2013-02-14       Impact factor: 22.113

2.  Impact of Cytomegalovirus Reactivation and Natural Killer Reconstitution on Outcomes after Allogeneic Hematopoietic Stem Cell Transplantation: A Single-Center Analysis.

Authors:  Taiki Ando; Taisei Suzuki; Yasufumi Ishiyama; Satoshi Koyama; Takayoshi Tachibana; Masatsugu Tanaka; Heiwa Kanamori; Hideaki Nakajima
Journal:  Biol Blood Marrow Transplant       Date:  2019-09-26       Impact factor: 5.742

3.  CMV reactivation drives posttransplant T-cell reconstitution and results in defects in the underlying TCRβ repertoire.

Authors:  Yvonne Suessmuth; Rithun Mukherjee; Benjamin Watkins; Divya T Koura; Knut Finstermeier; Cindy Desmarais; Linda Stempora; John T Horan; Amelia Langston; Muna Qayed; Hanna J Khoury; Audrey Grizzle; Jennifer A Cheeseman; Jason A Conger; Jennifer Robertson; Aneesah Garrett; Allan D Kirk; Edmund K Waller; Bruce R Blazar; Aneesh K Mehta; Harlan S Robins; Leslie S Kean
Journal:  Blood       Date:  2015-04-07       Impact factor: 22.113

4.  Acute GVHD results in a severe DC defect that prevents T-cell priming and leads to fulminant cytomegalovirus disease in mice.

Authors:  Matthew E Wikstrom; Peter Fleming; Rachel D Kuns; Iona S Schuster; Valentina Voigt; Gregory Miller; Andrew D Clouston; Siok-Keen Tey; Christopher E Andoniou; Geoffrey R Hill; Mariapia A Degli-Esposti
Journal:  Blood       Date:  2015-06-30       Impact factor: 22.113

5.  Viral reactivations and associated outcomes in the context of immune reconstitution after pediatric hematopoietic cell transplantation.

Authors:  Rick Admiraal; Coco C H de Koning; Caroline A Lindemans; Marc B Bierings; Annemarie M J Wensing; A Birgitta Versluys; Tom F W Wolfs; Stefan Nierkens; Jaap Jan Boelens
Journal:  J Allergy Clin Immunol       Date:  2017-04-07       Impact factor: 10.793

6.  Comparable anti-CMV responses of transplant donor and third-party CMV-specific T cells for treatment of CMV infection after allogeneic stem cell transplantation.

Authors:  Xu-Ying Pei; Xue-Fei Liu; Xiang-Yu Zhao; Meng Lv; Xiao-Dong Mo; Ying-Jun Chang; Qian-Nan Shang; Yu-Qian Sun; Yu-Hong Chen; Lan-Ping Xu; Yu Wang; Xiao-Hui Zhang; Kai-Yan Liu; Xiao-Jun Huang
Journal:  Cell Mol Immunol       Date:  2022-01-11       Impact factor: 22.096

7.  HLA-DP mismatch and CMV reactivation increase risk of aGVHD independently in recipients of allogeneic stem cell transplant.

Authors:  Armin Ghobadi; Denái R Milton; Lohith Gowda; Gabriela Rondon; Roy F Chemaly; Amir Hamdi; Amin Alousi; Aimaz Afrough; Betul Oran; Stefan Ciurea; Partow Kebriaei; Uday R Popat; Muzaffar H Qazilbash; Elizabeth J Shpall; Richard E Champlin; Qaiser Bashir
Journal:  Curr Res Transl Med       Date:  2019-01-23       Impact factor: 4.513

8.  Early lymphocyte recovery predicts superior outcomes after unmanipulated haploidentical blood and marrow transplant for acute myeloid leukemia.

Authors:  Qiang Fu; Lan-Ping Xu; Xiao-Hui Zhang; Yu Wang; Ying-Jun Chang; Xiao-Jun Huang
Journal:  Clin Transplant       Date:  2016-06-27       Impact factor: 2.863

Review 9.  B Cell Reconstitution and Influencing Factors After Hematopoietic Stem Cell Transplantation in Children.

Authors:  Nicolaas G van der Maas; Dagmar Berghuis; Mirjam van der Burg; Arjan C Lankester
Journal:  Front Immunol       Date:  2019-04-12       Impact factor: 7.561

10.  Rapid reconstitution of regulatory T-cell subsets is associated with reduced rates of acute graft-versus-host disease and absence of viremia after cord blood transplantation in children with reduced-intensity conditioning using alemtuzumab.

Authors:  Xiaohua Chen; Memphis Hill; Mark Vander Lugt; Maria Escolar; Zhou Fang; Wei Chen; Paul Szabolcs
Journal:  Cytotherapy       Date:  2020-02-21       Impact factor: 6.196

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.